<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01499459</url>
  </required_header>
  <id_info>
    <org_study_id>11111111</org_study_id>
    <secondary_id>1111111</secondary_id>
    <nct_id>NCT01499459</nct_id>
  </id_info>
  <brief_title>Autologous Mesenchymal Stem Cell Transplantation in Liver Cirrhosis</brief_title>
  <official_title>Efficacy of Exvivo Expanded Autologous Mesenchymal Stem Cell Transplantation Via Peripheral Vein in Patients With Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saglik Bilimleri Universitesi Gulhane Tip Fakultesi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saglik Bilimleri Universitesi Gulhane Tip Fakultesi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aiming to investigate the efficacy of autologous mesenchymal stem cell (MSC)
      transplantation in 25 randomized patients with liver cirrhosis autologous mesenchymal stem
      cell will be derived from patients' bone marrows and will be infused via peripheral vein.
      Liver biopsies will be performed in every patient in the beginning and at 6th month.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">August 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical improvement</measure>
    <time_frame>clinical improvement parameters will be assessed six month after mesenchymal stem cell transplantation</time_frame>
    <description>biochemical and hematologic parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>liver regeneration</measure>
    <time_frame>6.th month after MSC transplantation</time_frame>
    <description>histopathologic assesments comparing before and at 6th month liver biopsies</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>autologous mesenchymal stem cell transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>autologous mesenchymal stem cell transplantation</intervention_name>
    <description>Every patient is given 1x106 MSCs per kg infused via peripheral vein.</description>
    <arm_group_label>autologous mesenchymal stem cell transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  radiological, clinical and histopathological diagnosis of liver cirrhosis

          -  absence of hepatocellular carcinoma or any malignancies

          -  no psychiatric disorder

          -  no serous cardiovascular and pulmonary comorbidities

          -  serum total bilirubin levels less than 5 mg/dL

          -  platelet counts more than 30.000 mm3

          -  more than one year follow up period after initiation of antiviral drugs

        Exclusion Criteria:

          -  alcohol intake in last one year

          -  initiation of antiviral medication in last one year

          -  systemic diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>murat kantarcioglu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saglik Bilimleri Universitesi Gulhane Tip Fakultesi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gulhane Military Medical Academy Department of Gastroenterology</name>
      <address>
        <city>Ankara</city>
        <zip>06018</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2011</study_first_submitted>
  <study_first_submitted_qc>December 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2011</study_first_posted>
  <last_update_submitted>March 20, 2012</last_update_submitted>
  <last_update_submitted_qc>March 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saglik Bilimleri Universitesi Gulhane Tip Fakultesi</investigator_affiliation>
    <investigator_full_name>Murat Kantarcioglu</investigator_full_name>
    <investigator_title>Gulhane Military Medical Academy</investigator_title>
  </responsible_party>
  <keyword>liver cirrhosis</keyword>
  <keyword>autologous mesenchymal stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>July 3, 2013</submitted>
    <returned>September 9, 2013</returned>
    <submitted>January 5, 2014</submitted>
    <returned>February 15, 2014</returned>
    <submitted>May 7, 2014</submitted>
    <returned>June 5, 2014</returned>
    <submitted>November 14, 2014</submitted>
    <returned>November 20, 2014</returned>
    <submitted>December 19, 2014</submitted>
    <returned>January 6, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

